Sign in

Raajit Rampal

@raajitrampal.bsky.social
72 followers 65 following 9 posts

Physician-Scientist investigating and treating Myeloproliferative Neoplasms and Acute Myeloid Leukemia.

PostsRepliesMedia
Reposted by Raajit Rampal
Anand Patel @anand-88-patel.bsky.social · 01/04/2025
Glad to share the finalized version of a Haematologica review by @raajitrampal.bsky.social and me focused on accelerated/blast-phase MPNs! haematologica.org/article/view...
011
Raajit Rampal @raajitrampal.bsky.social · 10/03/2025
Out today in @NatureMedicine phase 3 data from thh MANIFEST-2 study nature.com/articles/s41... @aarongerds.bsky.social @mpndoc.bsky.social @kuykendallmd.bsky.social @rubenmesamd.bsky.social
nature.com
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial - Nature Medicine
In a randomized phase 3 trial, the combination of the BET inhibitor pelabresib with the JAK inhibitor ruxolitinib resulted in a significantly higher spleen volume reduction from baseline versus placeb...
132
Reposted by Raajit Rampal
Ross Levine MD @rosslevinemd.bsky.social · 08/02/2025
@mskcancercenter.bsky.social cycle for survival! Time to ride and raise money for rare cancers
1132
Reposted by Raajit Rampal
Carl T. Bergstrom @carlbergstrom.com · 08/02/2025
1. Today the NIH director issued a new directive slashing overhead rates to 15%. I want to provide some context on what that means and why it matters. grants.nih.gov/grants/guide...
grants.nih.gov
NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates NOT-OD-25-068. OD
25469974077
Reposted by Raajit Rampal
Miguel Perales MD @drmiguelperales.bsky.social · 07/02/2025
Important report in @nejm.org from @mskcancercenter.bsky.social CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 #CARTcells #mmsm www.nejm.org/doi/full/10....
nejm.org
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | NEJM
Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case o...
0157
Raajit Rampal @raajitrampal.bsky.social · 06/02/2025
I just registered for Cycle for Survival to support MPN research at MSKCC. My ride is March 7 and I’m trying to raise as much as I can by then to help people with MPNs Make your 100% tax-deductible donation here secure2.convio.net/mskcc/site/T...
secure2.convio.net
Cycle for Survival: The Movement to Beat Rare Cancers
Support rare cancer research at Memorial Sloan Kettering Cancer Center.
030
Reposted by Raajit Rampal
Nature Reviews Cancer @natrevcancer.nature.com · 27/01/2025
#REVIEW Vallot, Lupien and Lasine describe how epigenomic heterogeneity generates dynamic reservoirs of tumour cell states, which can be leveraged in the design of novel therapies. 📖 👉 bit.ly/40PCQ...
bit.ly
Epigenomic heterogeneity as a source of tumour evolution - Nature Reviews Cancer
Single-cell epigenomic technologies are refining our understanding of cancer evolution.
0148